Initially described in a case report in 2006, subsequent postmarketing reports of acute pancreatitis in patients treated with exenatide as well as in patients treated with the DPP-4 inhibitor sitagliptin (8), the first DPP-4 inhibitor approved for use in patients with T2DM, have led to a focus on both the preclinical and clinical experiences with exenatide, other members of the GLP-1 agonist class, and the DPP-4 inhibitor class. The gene discussed is GCG; the disease is type 2 diabetes mellitus.